

RECEIVED

OCT 30 2002

TECH CENTER 1600/2900

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	2	of	2	Application Number	10/080,772
				Filing Date	February 22, 2002
				First Named Inventor	Janet K. Yamamoto
				Group Art Unit	1645
				Examiner Name	unknown
				Attorney Docket Number	UF-267XC1

RECEIVED

NOV 07 2002

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
<i>hjy</i>	R1	NISHINO, Y. et al. "Major Core Proteins, p24s, of Human, Simian, and Feline Immunodeficiency Viruses are Partly Expressed on the Surface of the Virus-Infected Cells" <i>Vaccine</i> , 1992, pp. 677-683, Vol. 10, No. 10.		
	R2	STEINMAN, R. et al. "Biochemical and Immunological Characterization of the Major Structural Proteins of Feline Immunodeficiency Virus" <i>Journal of General Virology</i> , 1990, pp. 701-706, Vol. 71.		
	R3	STRANDSTROM, H.V. et al. "Studies with Canine Sera that Contain Antibodies which Recognize Human Immunodeficiency Virus Structural Proteins" <i>Cancer Research</i> , 1990, pp. 5628s-5630s, Vol. 50.		
	R4			
	R5			
	R6			
	R7			
	R8			
	R9			
	R10			
	R11			
	R12			
	R13			

Examiner Signature

Date Considered
1303/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+ TECH CENTER 1600/2900



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

FF 11 +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Group Art Unit	1645
Examiner Name	unknown

Attorney Docket Number

UF-267XC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
hy	R1	ABBAS, A. K. et al., In <u>Cellular and Molecular Immunology</u> , 4th edition, 2000, pp. 196-199, W.B. Saunders Company, Philadelphia.	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

RECEIVED

AUG 20 2002

TECH CENTER 1600/2900

Examiner Signature		Date Considered	3/23/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

OCT 30 2002

TECH CENTER 1600/2900
PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Art Unit	1645
Examiner Name	unknown

Attorney Docket Number

UF-267XC1

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	U1			
	U2			
	U3			
	U4			
	U5			
	U6			
	U7			
	U8			
	U9			
	U10			
	U11			
	U12			
	U13			
	U14			
	U15			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	- Number ⁴ - Kind Code ⁵ (if known)			
<i>kd</i>	F1	EP	0 860 504	A1	08-26-1998	Idexx Laboratories, Inc
<i>kd</i>	F2	WO	94/02613	A1	02-03-1994	Pitman-Moore, Inc.

Examiner Signature

Date Considered

3/23/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

#13
+

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

6

Complete if Known

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	UF-267XC1

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
FEB 22 2002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
hp	U1	US-4,358,535	11-09-1982	Falkow et al.	All
	U2	US-4,361,537	11-30-1982	Deutsch et al.	All
	U3	US-4,683,195	07-28-1987	Mullis et al.	All
	U4	US-4,683,202	07-28-1987	Mullis	All
	U5	US-4,708,818	11-24-1987	Montagnier et al.	All
	U6	US-4,800,159	01-24-1989	Mullis et al.	All
	U7	US-4,861,720	08-29-1989	Pedersen et al.	All
	U8	US-5,037,753	08-06-1991	Pedersen et al.	All
	U9	US-5,055,391	10-08-1991	Montagnier et al.	All
	U10	US-5,108,891	04-28-1992	Croxson	All
	U11	US-5,118,602	06-02-1992	Pedersen et al.	All
	U12	US-5,135,684	08-04-1992	Mohn et al.	All
	U13	US-5,160,701	11-03-1992	Brown, III et al.	All
	U14	US-5,275,813	01-04-1994	Yamamoto et al.	All
	U15	US-5,510,106	04-23-1996	Yamamoto et al.	All

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	- Number ⁴ - Kind Code ⁵ (if known)			
hp	F1	WO	99/60988 A2	University of Florida	All	
	F2					
	F3					
	F4					

Examiner Signature		Date Considered	8/28/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/080,772				
Filing Date	February 22, 2002				
First Named Inventor	Janet K. Yamamoto				
Art Unit	1645				
Examiner Name	unknown				
Sheet	2	of	6	Attorney Docket Number	UF-267XC1

REC-AUG-14-2002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
L-6	U16	US-5,530,101	06-25-1996	Queen et al.	— — All
	U17	US-5,565,319	10-15-1996	Pedersen et al.	1 1 All
	U18	US-5,585,098	12-17-1996	Queen et al.	All
	U19	US-5,693,762	12-02-1997	Queen et al.	All
	U20	US-5,807,715	09-15-1998	Morrison et al.	All
	U21	US-5,846,825	12-08-1998	Yamamoto	All
	U22	US-5,922,533	07-13-1999	Vallari et al.	All
	U23	US-5,219,725	06-15-1993	O'Connor et al.	✓ ✓ All
	U24	US-			
	U25	US-			
	U26	US-			
	U27	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY			
	F8					
	F9					
	F10					
	F11					
	F12					
	F13					
	F14					

Examiner Signature

Date Considered

3/21/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

O I P E
AUG 12 2002

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. GMBH 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

6

Complete if Known

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Group Art Unit	1645
Examiner Name	unknown

Attorney Docket Number

UF-267XC1

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
MAY 2002
20020520**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/JY	R1	ACKLEY, C. D. et al. "Immunologic Abnormalities in Pathogen-Free Cats Experimentally Infected with Feline Immunodeficiency Virus" <i>Journal of Virology</i> , 1990, pp. 5652-5655, Vol. 64, No. 11.	
/JY	R2	AZOCAR, J. et al. "Susceptibility of Human Cell Lines to Feline Leukemia Virus and Feline Sarcoma Virus" <i>J. Natl Cancer Inst.</i> , 1979, pp. 1179-1184, Vol. 63, No. 5.	
	R3	BISHOP, S. A. et al. "Vaccination with Fixed Feline Immunodeficiency Virus (FIV) Infected Cells: Protection, Breakthrough and Specificity of Response" <i>Vaccine</i> , 1996, pp. 1243-1250, Vol. 14, No. 3.	
	R4	BUTERA, S. T. et al. "Survey of Veterinary Conference Attendees for Evidence of Zoonotic Infection by Feline Retroviruses" <i>J. Am. Vet. Med. Assoc.</i> , 2000, pp. 1475-1479, Vol. 217, No. 10.	
	R5	"HIV and Other Retroviruses" CDC Report, HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, pp. 1-20, www.cdc.gov/ncidod/dastlr/retrovirology/default.htm .	
	R6	EGBERINK, H. F. et al., "Use of Western Blot and Radioimmunoprecipitation for Diagnosis of Feline Leukemia and Feline Immunodeficiency Virus Infections" <i>J. Am. Vet. Med. Assoc.</i> , 1991, pp. 1339-1342, Vol. 199, No. 10.	
	R7	GOUDSMIT, J. et al. "LAV/HTLV-III gag Gene Product p24 Shares Antigenic Determinants with Equine Infectious Anemia Virus but Not with Visna Virus or Caprine Arthritis Encephalitis Virus" <i>Intervirology</i> , 1986, pp. 169-173, Vol. 26.	
	R8	HOHDATSU, T. et al. "Genetic Subtyping and Epidemiological Study of Feline Immunodeficiency Virus by Nested Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Analysis of the gag Gene" <i>J. Virol. Methods</i> , 1998, pp. 107-111, Vol. 70.	
	R9	HOSIE, M. J. et al. "Serological Responses of Cats to Feline Immunodeficiency Virus" <i>AIDS</i> , 1990, pp. 215-220, Vol. 4.	
	R10	JARRETT, O. et al. "Determinants of the Host Range of Feline Leukaemia Viruses" <i>J. Gen. Virol.</i> , 1973, pp. 169-175, Vol. 20.	
	R11	JOHNSTON, J. C. et al. "Minimum Requirements for Efficient Transduction of Dividing and Nondividing Cells by Feline Immunodeficiency Virus Vectors" <i>Journal of Virology</i> , 1999, pp. 4991-5000, Vol. 73, No. 6.	
	R12	JOHNSTON, J. et al. "Productive Infection of Human Peripheral Blood Mononuclear Cells by Feline Immunodeficiency Virus: Implications for Vector Development" <i>Journal of Virology</i> , 1999, pp. 2491-2498, Vol. 73, No. 3.	
	R13	KHABBAZ, R. F. et al. "Brief Report: Infection of a Laboratory Worker with Simian Immunodeficiency Virus" <i>The New England Journal of Medicine</i> , 1994, pp. 172-177, Vol. 330, No. 3.	

Examiner Signature

Date Considered
3/23/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

6

Complete if Known

Application Number	10/080,772	AUS
Filing Date	February 22, 2002	100/200
First Named Inventor	Janet K. Yamamoto	2002
Group Art Unit	1645	REC'D
Examiner Name	unknown	E
Attorney Docket Number	UF-267XC1	

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
RJ	R14	KHABBAZ, R. F. et al. "Simian Immunodeficiency Virus Needlestick Accident in a Laboratory Worker" <i>The Lancet</i> , 1992, pp. 271-273, Vol. 340, No. 8813.
	R15	KAKINUMA, S. et al. "Nucleotide Sequence of Feline Immunodeficiency Virus: Classification of Japanese Isolates into Two Subtypes Which Are Distinct from Non-Japanese Subtypes" <i>Journal of Virology</i> , 1995, pp. 3639-3646, Vol. 69, No. 6.
	R16	KOHLER, G. et al. "Derivation of Specific Antibody-Producing Tissue Culture and Tumor Lines by Cell Fusion" <i>Eur. J. Immunol.</i> , 1976, pp. 511-519, Vol. 6.
	R17	LOUWAGIE, J. et al. "Phylogenetic Analysis of gag Genes from 70 International HIV-1 Isolates Provides Evidence for Multiple Genotypes" <i>AIDS</i> , 1993, pp. 769-780, Vol. 7, No. 6.
	R18	MATSUO, K. et al. "Highly Conserved Epitope Domain in Major Core Protein p24 is Structurally Similar Among Human, Simian and Feline Immunodeficiency Viruses" <i>Journal of General Virology</i> , 1992, pp. 2445-2450, Vol. 73.
	R19	MERRIFIELD, R. B. "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <i>J. Amer. Chem. Soc.</i> , 1963, pp. 2149-2154, Vol. 85.
	R20	MORRISON, S. L. et al. "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains" <i>Proc. Natl. Acad. Sci. USA</i> , 1984, pp. 6851-6855, Vol. 81.
	R21	MURPHY, F. A. et al. "Virus Taxonomy" In <i>Virology</i> , Second Edition, 1990, pp. 9-35, Raven Press, Ltd., New York.
	R22	NORWAY, R. M. et al. "Thymic Lesions in Cats Infected with a Pathogenic Molecular Clone or an ORF-A/2-Deficient Molecular Clone of Feline Immunodeficiency Virus" <i>Journal of Virology</i> , 2001, pp. 5833-5841, Vol. 75, No. 13.
	R23	OLMSTED, R. A. et al. "Molecular Cloning of Feline Immunodeficiency Virus" <i>Proc. Natl. Acad. Sci. USA</i> , 1989, pp. 2448-2452, Vol. 86, No. 7.
	R24	OLMSTED, R. A. et al. "Nucleotide Sequence Analysis of Feline Immunodeficiency Virus: Genome Organization and Relationship to Other Lentiviruses" <i>Proc. Natl. Acad. Sci. USA</i> , 1989, pp. 8088-8092, Vol. 86, No. 20.
	R25	OU, C. Y. et al. "DNA Amplification for Direct Detection of HIV-1 in DNA of Peripheral Blood Mononuclear Cells" <i>Science</i> , 1988, pp. 295-297, Vol. 239, No. 4837.
	R26	PEDERSEN, N. C. et al. "Isolation of a T-Lymphotropic Virus From Domestic Cats with an Immunodeficiency-Like Syndrome" <i>Science</i> , 1987, pp. 790-793, Vol. 235, No. 4790.

Examiner Signature

Date Considered
7/23/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. GPO 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
AUG 14 2002
2002
DOC

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

6

Complete if Known

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Group Art Unit	1645
Examiner Name	unknown

Attorney Docket Number

UF-267XC1

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
R27	POESCHLA, E. M. et al. "CXCR4 Is Required by a Nonprimate Lentivirus: Heterologous Expression of Feline Immunodeficiency Virus in Human, Rodent, and Feline Cells" <i>Journal of Virology</i> , 1998, pp. 6858-6866, Vol. 72, No. 8.	
R28	PU, R. et al. "MHC-Restricted Protection of Cats Against FIV Infection by Adoptive Transfer of Immune Cells from FIV-Vaccinated Donors" <i>Cellular Immunology</i> , 1999, pp. 30-43, Vol. 198.	
R29	PU, R. et al. "Dual-subtype FIV Vaccine Protects Cats Against <i>In Vivo</i> Swarms of Both Homologous and Heterologous Subtype FIV Isolates" <i>AIDS</i> , 2001, pp. 1225-1237, Vol. 15.	
R30	RICHARDSON, J. et al. "Shared Usage of the Chemokine Receptor CXCR4 by Primary and Laboratory-Adapted Strains of Feline Immunodeficiency Virus" <i>Journal of Virology</i> , 1999, pp. 3661-3671, Vol. 73, No. 5.	
R31	RIGBY, M. A. et al. "Evolution of Structural Proteins of Feline Immunodeficiency Virus: Molecular Epidemiology and Evidence of Selection for Change" <i>Journal of General Virology</i> , 1993, pp. 425-437, Vol. 74.	
R32	RIGBY, M. A. et al. "Immunogenicity of a Peptide From a Major Neutralising Determinant of the Feline Immunodeficiency Virus Surface Glycoprotein" <i>Vaccine</i> , 1996, pp. 1095-1102, Vol. 14, No. 12.	
R33	SAIKI, R. K. et al. "Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia" <i>Science</i> , 1985, pp. 1350-1354, Vol. 230, No. 4732.	
R34	SARMA, P. S. et al. "Feline Leukemia and Sarcoma Viruses: Susceptibility of Human Cells to Infection" <i>Science</i> , 1970, pp. 1098-1100, Vol. 168, No. 3935.	
R35	SODORA, D. L. et al. "Identification of Three Feline Immunodeficiency Virus (FIV) env Gene Subtypes and Comparison of the FIV and Human Immunodeficiency Virus Type 1 Evolutionary Patterns" <i>Journal of Virology</i> , 1994, pp. 2230-2238, Vol. 68, No. 4.	
R36	TALBOTT, R. L. et al. "Nucleotide Sequence and Genomic Organization of Feline Immunodeficiency Virus" <i>Proc. Natl. Acad. Sci. USA</i> , 1989, pp. 5743-5747, Vol. 86, No. 15.	
R37	WILLETT, B. J. et al. "Shared Usage of the Chemokine Receptor CXCR4 by the Feline and Human Immunodeficiency Viruses" <i>Journal of Virology</i> , 1997, pp. 6407-6415, Vol. 71, No. 9.	
R38	WILLETT, B. J. et al. "Common Mechanism of Infection by Lentiviruses" <i>Nature</i> , 1997, p. 587, Vol. 385, No. 6617.	
R39	YAMAMOTO, J. K. et al. "Feline Immunodeficiency Syndrome—A Comparison Between Feline T-Lymphotropic Lentivirus and Feline Leukemia Virus" <i>Leukemia</i> , 1988, pp. 204S-215S, Vol. 2, No. 12 Supplement.	

Examiner Signature	Date Considered
--------------------	-----------------

3/23/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 6

Complete if Known

Application Number	10/080,772
Filing Date	February 22, 2005
First Named Inventor	Janet K. Yamamoto
Group Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	UF-267XC1

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
R3	R40	YAMAMOTO, J. K. et al. "Pathogenesis of Experimentally Induced Feline Immunodeficiency Virus Infection in Cats" Am. J. Vet. Res., 1998, pp. 1246-1258, Vol. 49, No. 8.
	R41	YAMAMOTO, J. K. et al. "Epidemiologic and Clinical Aspects of Feline Immunodeficiency Virus Infection in Cats From the Continental United States and Canada and Possible Mode of Transmission" J. Am. Vet. Med. Assoc., 1989, pp. 213-220, Vol. 194, No. 2.
	R42	YAMAMOTO, J. K. et al. "Experimental Vaccine Protection Against Homologous and Heterologous Strains of Feline Immunodeficiency Virus" Journal of Virology, 1993, pp. 601-605, Vol. 67, No. 1.
J	R43	JOHNSTON, J. B. et al. "Xenoinfection of Nonhuman Primates by Feline Immunodeficiency Virus" Current Biology, 2001, pp. 1109-1113, Vol. 11, No. 14.
	R44	
	R45	
	R46	
	R47	
	R48	
	R49	
	R50	
	R51	
	R52	

TECH CENTER 1600/2900

AUG 14 2002

RECEIVED

Examiner Signature		Date Considered	3/25/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.